DM Capital
DM Capital Ltd. is a venture capital and private equity firm founded in 2001 and headquartered in Shenzhen, China, with additional offices in major cities including Beijing, Guangzhou, and Zurich. The firm specializes in early-stage and growth investments, primarily focusing on the healthcare sector. Its investment interests encompass a wide range of areas such as innovative medical technologies, artificial intelligence, biomedicine, genetic technology, and advanced healthcare equipment. DM Capital also engages in industrial investments and provides financial advisory services. As the parent company of DM Healthcare Investment Co., Ltd., it further extends its investment activities to overseas healthcare industries. The firm is committed to fostering technology innovation and creating value through strategic investments in companies involved in health technology, biopharmaceuticals, and medical devices. Through its subsidiary, DM Fund Management Limited, DM Capital actively manages funds that target public Chinese companies listed on international exchanges, while also facilitating mergers and acquisitions between Chinese and Western markets.
Rege Nephro is a biotech company specializing in R&D, production, and marketing of renal disease therapeutics. It utilizes induced pluripotent stem cell (iPSC)-based technology from the Center for iPS Cell Research and Application (CiRA), Kyoto University. It is developing therapeutics and cell therapy for kidney, liver, and pancreas diseases.
Shang Gong is a Beijing Based Healthcare Start Up.
Sigilon Therapeutics is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. To address these therapy problems, Sigilon is developing its Shielded Living TherapeuticsTM platform. Sigilon is designing product candidates to provide a wide range of functions or therapeutic molecules that may be missing or deficient in the body, leveraging advances in cell differentiation and engineering, as well as cutting-edge innovations in its proprietary biocompatible materials—potentially resulting in functional cures for patients with a wide range of acute and chronic diseases.
IVIVA Medical was founded with the goal of developing autologous tissue constructs as a solution to end-state renal disease (ESRD). End-stage renal disease affects over 500,000 patients in the United States and despite transplant being the only definitive treatment for ESRD, most will never receive a donor kidney. Our team is leveraging emerging complementary technologies in tissue engineering, 3D additive manufacturing, and stem cell biology in order to realize the potential of regenerative medicine to end donor organ shortage. We are developing bioartificial platforms and systems not only to provide therapies but to serve as the foundational building blocks for the next generation of engineered functionalized tissues.
ULab develops a breakthrough software technology for digital dental treatment planning. It’s proprietary architecture and fully automated features enable orthodontists, for the first time, to create chairside treatment plans in less than 5 minutes.
Jiahong DentalLab provides denture services. It is dedicated to giving oral patients all over the world denture restoration products and solutions that are more effective and secure. They offer a cnc-pure titanium bracket, a planting guide, a pure titanium light-cured composite resin bridge, an implant suprabridge, a zirconia all-ceramic bridge on the upper part of the implant, a vitaline stent, an active fix peek, a zirconia all-ceramic bridge, and a zirconia all-ceramic crown and bridge.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.